http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2073696-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_69ece09bafee7e0c49d1f7951a3faa2c |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-75 |
classificationIPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-75 |
filingDate | 1991-01-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e92eff4ee2be27dc38b42530da51675d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_938007e51302e2725395b9c480ce1237 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9e3c051fa431e3a85be3b858234a9140 |
publicationDate | 1991-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | CA-2073696-A1 |
titleOfInvention | Cyclic peptides containing arg-gly-asp flanked by proline |
abstract | A small cyclic peptide is provided having high affinity for the platelet GP IIbIIIa receptor, which peptide is represented by formula .alpha. where R1 and R4 are from 0 to 4 amino acids, R3 is from 1 to 4 amino acids; R2 is -CH2CO- or from 1 to 4 amino acids; Xaa8 may be Met, Phe, nLeu, Ile, Asp, Lys, Arg and Gln; and Z is a linking group, either disulfide, thioether or amide, but preferably disulfide. Preferred cyclic peptides exhibiting high inhibition potency in a platelet aggregation assay are represented by formula .beta. where Xaa2, Xaa3 and Xaa4 may be any amino acid but preferably are Arg, Ile and Pro, respectively. Xaa8 is preferably Met, Phe or nLeu; Xaa10 when present, is preferably Ala; and Xaa11, when present, is preferably Ala or Asp. These compounds may be effectively employed in a pharmaceutical composition containing a pharmaceutically acceptable excipient for reducing platelet aggregation in a mammal. The pharmaceutical composition is especially useful in treating a mammal having an increased propensity for thrombus formation, and may be used in combination with an anticoagulant or thrombolytic agent. |
priorityDate | 1990-02-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 112.